Levothyroxine Potency Standards To Be Addressed By FDA Advisory Committees
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is focusing on potential “clinically significant concerns” and will address intraproduct issues before moving to questions of bioequivalence.